Table 1.
Patient demographics and baseline disease characteristics
| Age <70 years | Age ≥70 years | |||
|---|---|---|---|---|
| Carfilzomib group (n = 293) | Control group (n = 281) | Carfilzomib group (n = 103) | Control group (n = 115) | |
| Age, median years (range) | 60·0 (38·0–69·0) | 62·0 (31·0–69·0) | 74·0 (70·0–87·0) | 74·0 (70·0–91·0) |
| ECOG PS, n (%) | ||||
| 0 or 1 | 267 (91·1) | 262 (93·2) | 89 (86·4) | 99 (86·1) |
| 2 | 26 (8·9) | 19 (6·8) | 14 (13·6) | 16 (13·9) |
| Cytogenetic risk by FISH at study entry, n (%) | ||||
| High risk | 42 (14·3) | 43 (15·3) | 6 (5·8) | 9 (7·8) |
| Standard risk | 102 (34·8) | 111 (39·5) | 45 (43·7) | 59 (51·3) |
| Unknown | 149 (50·9) | 127 (45·2) | 52 (50·5) | 47 (40·9) |
| Creatinine clearance, n (%) | ||||
| 30 to <50 ml/min | 10 (3·4) | 17 (6·0) | 15 (14·6) | 14 (12·2) |
| ≥50 ml/min | 283 (96·6) | 260 (92·5) | 87 (84·5) | 98 (85·2) |
| Unknown/other value | 0 | 4 (1·4) | 1 (1·0) | 3 (2·6) |
| Serum β2‐microglobulin level, n (%) | ||||
| <2·5 mg/l | 61 (20·8) | 61 (21·7) | 16 (15·5) | 16 (13·9) |
| ≥2·5 mg/l | 232 (79·2) | 220 (78·3) | 87 (84·5) | 99 (86·1) |
| Prior therapy, n (%) | ||||
| Bortezomib | 197 (67·2) | 186 (66·2) | 64 (62·1) | 74 (64·3) |
| Lenalidomide | 56 (19·1) | 52 (18·5) | 23 (22·3) | 26 (22·6) |
ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization.